Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SYMBRAVO | Axsome Therapeutics | N-215431 RX | 2025-01-30 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
maxalt | New Drug Application | 2011-09-13 |
maxalt maxalt-mlt | New Drug Application | 2022-06-01 |
maxalt-mlt | New Drug Application | 2011-04-04 |
rizafilm | New Drug Application | 2024-01-10 |
rizatriptan | ANDA | 2024-08-29 |
rizatriptan benzoate | ANDA | 2025-02-01 |
rizatriptan benzoate odt | ANDA | 2025-01-22 |
rizatriptan benzoate rizatriptan benzoate | ANDA | 2021-03-02 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Rizatriptan Benzoate, Rizafilm, Gensco | |||
9301948 | 2034-07-30 | DS, DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | 2 | 24 | 9 | 6 | 41 |
Headache | D006261 | — | R51 | — | — | 5 | 3 | 1 | 9 |
Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | 1 | 1 | — | 2 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | 1 | — | 1 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | 1 | — | 1 |
Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | 1 | — | 1 |
Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | — | — | 1 | — | 1 |
Post-concussion syndrome | D038223 | EFO_1001827 | F07.81 | — | — | — | 1 | — | 1 |
Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | — | 1 | — | — | 1 |
Migraine with aura | D020325 | EFO_0005295 | G43.1 | — | — | 1 | — | — | 1 |
Vertigo | D014717 | — | H81.39 | — | 1 | 1 | — | — | 1 |
Recurrence | D012008 | — | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Post-traumatic headache | D051298 | — | G44.3 | — | — | — | — | 1 | 1 |
Motion sickness | D009041 | — | T75.3 | — | — | — | — | 1 | 1 |
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Drug common name | Rizatriptan |
INN | rizatriptan |
Description | Rizatriptan is a member of tryptamines. It has a role as a serotonergic agonist, a vasoconstrictor agent and an anti-inflammatory drug. It is functionally related to a N,N-dimethyltryptamine. |
Classification | Small molecule |
Drug class | antimigraine agents (5-HT1 receptor agonists); sumatriptan derivatives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12 |
PDB | — |
CAS-ID | 144034-80-0 |
RxCUI | — |
ChEMBL ID | CHEMBL905 |
ChEBI ID | 48273 |
PubChem CID | 5078 |
DrugBank | DB00953 |
UNII ID | 51086HBW8G (ChemIDplus, GSRS) |